Pfizer-BioNTech Vax Approval of Omicron KP.2 Variant

eAwazMedicine

KIRKLAND 4 – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages. The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals 5 …

PADCEV approved by Health Canada to treat advanced bladder cancer

eAwazMedicine

KIRKLAND – Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) an antibody-drug conjugate (ADC) in combination with pembrolizumab, a PD-1 inhibitor, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) with no prior systemic therapy for mUC. The approval was made under the Health Canada Priority Review process, after having met the …

Sumitomo Pharma and Pfizer Canada Announce Availability of MYFEMBREE® in Canada

eAwazMedicine

Kirkland – In partnership with Sumitomo Pharma Canada, Inc., Pfizer Canada ULC is proud to announce that supply of MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone acetate tablets 0.5 mg tablets) is now available in Canada by prescription for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, as well as for the management of …